Vigilant Diagnostics' vision is to revolutionize Point-of-Care (POC) testing with an advanced, solid-state Lateral Flow Assay (LFA) reader that is designed for speed, accuracy, quantitative results, and affordability. Our current prototype readers are for use in controlled research settings to help teams explore sensitivity constraints in Lateral Flow Assays -- that is, they are for RUO (Research Use Only) at this time. These are not yet commercially available clinical devices.
The targeted launch date for our commercial reader is 2027. In the interim, prototype RUO engagements are available by application. Eligible researchers are encouraged to contact us. These engagements are for the purpose of learning, feasibility, and feedback. To inquire, please use the "Contact" link above.
Our prototype readers support a wide range of Lateral Flow Assay (LFA) tests, enabling research to detect infectious diseases, biomarkers, and other conditions. With enhanced sensitivity and automated functionality, the reader is designed to deliver faster and more reliable results than traditional methods.
Vigilant Desktop Reader (currently Research Use Only)
Solid-State Reader Advancements
Our prototype solid-state readers feature our cutting-edge, patented Thermal Contrast Amplification (TCA) technology. The current desktop model configuration has been designed to be appropriate for physicians’ offices and labs. In the future, a handheld version can be tailored for a strategic partner for field use.
Broad Applications for Infectious Diseases and More
Vigilant’s current RUO prototype readers are designed to read a vast array of LFA-based tests already available, including those for cardiovascular markers, hormone levels, and chronic disease monitoring. This versatility enables researchers to perform diverse diagnostic tests with ease and accuracy.
How It Works
Using our prototype RUO reader is simple and efficient:
- The user applies a specimen sample to an LFA test strip.
- After the normal analysis time for the LFA (typically under 15 minutes), the cartridge containing the strip is inserted into the reader.
- The device automatically scans the sample, delivering a semi-quantitative or quantitative result in less than five seconds.
The results are highly sensitive and precise, enabling earlier detection and timely intervention for various health conditions.
Proven Performance
Vigilant Diagnostics has partnered over the years with academic and government institutions to evaluate our TCA readers, has received funding from NIH and CDC, and has achieved excellent results across multiple applications. With our technology, standard LFAs typically realize a 10X increase in sensitivity, while Vigilant-optimized LFAs have shown sensitivity of 1000x, rivaling that of PCR and ELISA diagnostics at a fraction of the cost and time.
Commercial Availability
Vigilant’s new desktop solid-state reader is available as an "alpha" prototype for specific application validation by select strategic partners and researchers. (That is, currently they are for Research Use Only.) These units will demonstrate the value of our TCA technology, and are intended to provide the base platform for configuration to the specifications of our strategic licensees. Design consideration was made to allow the unit to be configured in the future in portable form for field applications. Whether configured in desktop or portable form, these units are poised to transform LFA testing across healthcare and other markets.
Vigilant Diagnostics continues to innovate, with the objective of being able to deliver solutions to empower healthcare providers and others to make faster, more informed decisions for better diagnostic outcomes. To learn more, click the "Connect With Us" button below to arrange a briefing.
Ready to find out more about our reader?
Drop us a line today!